Quest Diagnostics Incorporated $DGX Stake Lifted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 42.1% in the third quarter, HoldingsChannel reports. The firm owned 23,604 shares of the medical research company’s stock after purchasing an additional 6,993 shares during the period. Nisa Investment Advisors LLC’s holdings in Quest Diagnostics were worth $5,501,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Integrated Advisors Network LLC increased its holdings in Quest Diagnostics by 41.4% during the 3rd quarter. Integrated Advisors Network LLC now owns 1,769 shares of the medical research company’s stock worth $412,000 after purchasing an additional 518 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in shares of Quest Diagnostics by 8.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 122,316 shares of the medical research company’s stock valued at $31,198,000 after buying an additional 9,770 shares during the last quarter. Diversify Advisory Services LLC boosted its stake in shares of Quest Diagnostics by 19.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 4,724 shares of the medical research company’s stock valued at $1,101,000 after buying an additional 778 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its stake in shares of Quest Diagnostics by 257.7% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,416 shares of the medical research company’s stock valued at $796,000 after buying an additional 2,461 shares during the last quarter. Finally, Net Worth Advisory Group grew its position in shares of Quest Diagnostics by 47.5% during the third quarter. Net Worth Advisory Group now owns 7,129 shares of the medical research company’s stock worth $1,662,000 after buying an additional 2,296 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Key Stories Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Third-quarter results beat estimates: Quest reported adjusted EPS of $3.00 versus the $2.87 consensus and revenue of $3.10 billion versus expectations of $3.05 billion. Revenue increased 10% year over year, while adjusted EPS rose 15.4%, reflecting stronger testing demand and margin improvement. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Quest now expects 2026 revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35, above consensus estimates of approximately $12.0 billion and $11.19, respectively. Organic requisition volume rose 14.4% in the quarter, and consumer-health revenue is expected to grow more than 30% for the year. Quest Diagnostics Earnings Takeaways
• Positive Sentiment: Valuation and momentum remain supportive: Coverage characterized DGX as potentially undervalued following the guidance increase, while Zacks highlighted the company’s long-term momentum profile. Quest Diagnostics Could Be Undervalued
• Neutral Sentiment: Deutsche Bank raised its price target to $245 from $232 but maintained a Hold rating, indicating improved expectations without a clear bullish endorsement. Deutsche Bank Adjusts Quest Diagnostics Price Target
• Negative Sentiment: Patient-data breach creates a major overhang: Quest disclosed unauthorized access to its Quanum Lab Services Manager, a system used to order tests and access results. The company confirmed that personal and health information was compromised, potentially exposing it to regulatory scrutiny, litigation, remediation costs, and reputational damage. Quest Diagnostics Patient Data Breach

Analysts Set New Price Targets

A number of brokerages recently issued reports on DGX. Robert W. Baird set a $262.00 price target on shares of Quest Diagnostics in a research note on Friday. JPMorgan Chase & Co. upped their price target on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. UBS Group reiterated a “neutral” rating and set a $250.00 price objective on shares of Quest Diagnostics in a research note on Monday. Weiss Ratings raised shares of Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a report on Wednesday. Finally, Barclays raised their price objective on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $244.27.

Quest Diagnostics Stock Performance

Shares of NYSE DGX opened at $241.49 on Friday. The company has a quick ratio of 1.46, a current ratio of 1.70 and a debt-to-equity ratio of 0.70. The firm’s 50-day moving average price is $237.67 and its two-hundred day moving average price is $216.82. Quest Diagnostics Incorporated has a 52-week low of $171.18 and a 52-week high of $248.84. The stock has a market capitalization of $26.65 billion, a P/E ratio of 24.05, a P/E/G ratio of 2.19 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.87 by $0.13. The company had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The business’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.60 earnings per share. As a group, sell-side analysts forecast that Quest Diagnostics Incorporated will post 11.23 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th were given a dividend of $0.86 per share. The ex-dividend date was Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.4%. Quest Diagnostics’s payout ratio is currently 36.52%.

Insider Buying and Selling

In related news, SVP Mark Delaney sold 1,600 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the transaction, the senior vice president directly owned 10,335 shares in the company, valued at $2,430,585.30. This represents a 13.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. Davis sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the transaction, the chief executive officer directly owned 122,423 shares of the company’s stock, valued at approximately $29,714,510.56. This trade represents a 7.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 34,277 shares of company stock worth $8,316,493 in the last three months. 0.88% of the stock is owned by insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.